A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

NCT06196203 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Higher-risk Myelodysplastic Syndromes

Interventions

DRUG: AK117
DRUG: Placebo
DRUG: Azacitidine

Sponsor

Akeso